Randomized pilot trial of ipratropium versus placebo in children with critical asthma.
Kaitlyn MurphyNabihah MahmoodDaniel CravenJohn GallagherKristie R RossRichard SpeicherAlexandre T RottaSteven L SheinPublished in: Pediatric pulmonology (2020)
Demographics, initial clinical severity score, and asthma histories were similar between groups. There was no significant difference in the median duration of high-intensity albuterol between the treatment group (17.5 [10.3-22.1] h) and placebo group (14.6 [12.7-24.5] days; p = .56). Similarly, there was no significant difference in pediatric intensive care unit length of stay (22.6 [21.1-33.6] vs. 21.4 [16.1-35.8] h; p = .74) or hospital length of stay (48.0 [41.8-59.8] vs. 47.3 [37.2-63.1] h; p = .67). In multivariate linear regression adjusting for identified confounders, treatment with ipratropium was not significantly associated with any of the three outcomes. Side effects were rare and occurred with equally between both groups CONCLUSIONS: Adjunctive therapy with ipratropium was not associated with decreased duration of high-intensity albuterol or shortened length of stay when compared to placebo. A larger, multicenter trial is warranted to confirm that ipratropium does not improve clinical outcomes.
Keyphrases
- high intensity
- double blind
- phase iii
- intensive care unit
- resistance training
- placebo controlled
- clinical trial
- chronic obstructive pulmonary disease
- open label
- phase ii
- young adults
- randomized controlled trial
- healthcare
- emergency department
- metabolic syndrome
- study protocol
- type diabetes
- adipose tissue
- combination therapy
- cystic fibrosis
- bone marrow
- allergic rhinitis
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- replacement therapy
- glycemic control